Connect with us

News

Medical cannabis breakthrough sees launch of first symptom-specific products

Published

on

Bazelet is Israel’s largest medical cannabis company

A medical cannabis company in Israel has launched the first-of-a-kind products designed to help specific symptoms. 

Israel’s largest medical cannabis company, Bazelet, has announced a breakthrough in medical cannabis products, launching multiple lines of terpene-enriched cannabis oils specifically designed for one of various indications and symptoms. 

Its terpene-enriched products are optimised for personal needs such as women’s health, specific types of pain – such as muscle, joint, neuropathic – improved night’s sleep and elderly population concerns.

The company has invented a unique way of formulating medical cannabis oils that doesn’t depend on developing new strains in order to form a large variety of better-performing new oils. 

It’s TOP technology generates improved new oils by blending extracts and by controlling their terpene content, particularly by enriching with scientific-based terpenes selection.

Bazelet’s scientific arm has devoted the last four years to finding which terpenes improve the performance of the cannabis oil for each indication or symptom and which ones have a negative effect. 

Analysis of big data from hundreds of thousands of users, careful study of pre-clinical and clinical data and a deep dive into mechanisms of action, has resulted in these new formulations specifically designed for different indications. 

Almost everyone is aware of Indica and Sativa strains, believed to be more suitable for night use and for day use, respectively. What is less known is that the majority of the terpenes responsible for the difference between the Indica nature and the Sativa nature are lost in the oil manufacturing. 

Bazelet enriches its oils with the lost terpenes and further improvement is gained by enriching with selected terpenes, for example enriching Sativa oils with terpenes that increase focus and alertness, making it more suitable for day function.

Cannabis inflorescence contains 10-20 different terpenes, varying in amount and proportion and determining the characteristic aroma of the various strains. 

Terpenes play an important medical role, individually and more importantly, in modulating the activity of the cannabinoids in the cannabis oil.

The terpene content of Bazelet oils is said to be 50-100 percent greater than those of common cannabis oils and are therefore referred to as terpenes-enriched.

Bazelet has filed around a dozen patent application families to protect its terpenes-enriched formulations and is ready to supply patent-protected terpenes blends to be added to extracts produced elsewhere in the world. 

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.